In the first 11 months of 2017, Russia imported the medicinal products for the total amount of 557.8 billion rubles (in prices set for release for free circulation, including VAT).
Compared to the same period of last year, the ruble-denominated growth was 4.3%. Over the year, the supplies of finished medicinal products increased by 9.2%, while the total imports of finished medicinal products reached 472.2 billion rubles. The imports of in-bulk products amounted to 85.6 billion rubles, which represents a significant decline (-16.4%).
In general, the results for November 2017 were in line with the overall trends of this year. During the year, the imports of finished medicinal products increased by 11.6% in ruble terms and reached 52.1 billion rubles. In November, the in-bulk supplies did not exceed 7.5 billion rubles (-26% compared to the same period of 2016).
Since the beginning of this year, the imports of in-bulk products demonstrated a fairly steady growth in physical terms, despite the decline in monetary terms (+7.3% when calculated in MDU). Over the period, the total imports of finished medicinal products and in-bulk products reached 37.5 billion MDU, but the general growth rate is still negative (-1.1%).
In terms of dynamics for the imports of finished medicinal products to Russia in 11 months of 2017, the absolute champion was Saudi Arabia. Over the past year, the imports of medicines from that country jumped by more than 9 times as they were propelled by deliveries of Suprax (Astellas). In term of dynamics for in-bulk imports during the period, the champion was Thailand. Over the year, the deliveries of in-bulk products from that country increased by almost 11 times in monetary terms. The growth was ensured by the supplies of Utrogestan (Besins Healthcare).